Literature DB >> 15713724

Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study.

John K Amory1, William J Bremner.   

Abstract

Testosterone (T) is not administered orally, because it has been reported to be rapidly metabolized by the liver. We hypothesized that sufficient doses of T or T enanthate (TE), administered orally in oil, would result in clinically useful elevations in serum T. We also hypothesized that coadministration of dutasteride (D) with T or TE would minimize increases in serum DHT seen previously with oral administration. Therefore, we conducted a pharmacokinetic study of oral T and TE in oil, with and without concomitant D, in normal men whose T production had been temporarily suppressed by the GnRH antagonist acyline. Thirteen healthy men (mean age, 24 +/- 6 yr) were enrolled and assigned to oral T (n = 7) and oral TE (n = 6) groups and were administered 200, 400, or 800 mg of either T or TE in sesame oil in the morning on 3 successive days 24 h after receiving acyline. Blood samples for measurement of serum T and dihydrotestosterone were obtained before T or TE administration and 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h after administration. Subjects were then administered D for 4 d before repeating the sequence of T or TE doses with D. Serum T was significantly increased in a dose-dependent fashion with the administration of oral T or TE in oil. Coadministration of D with oral T or TE significantly increased the 24-hr average serum T levels compared with administration of T or TE alone [average serum T after 400 mg dose, 8.7 +/- 3.0 nmol/l (T) and 8.3 +/- 5.7 nmol/l (TE) vs. 16.1 +/- 5.8 nmol/l (T +D) and 15.0 +/- 8.8 nmol/l (TE + D); P < 0.05 for T vs. T and D]. The administration of oral T or TE in oil combined with D results in unexpected and potentially therapeutic increases in serum T. Additional studies of this combination as a novel form of oral androgen therapy are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15713724     DOI: 10.1210/jc.2004-1221

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Hormone supplementation during aging: how much and when?

Authors:  K G Sorwell; J Garten; L Renner; A Weiss; V T Garyfallou; S G Kohama; M Neuringer; H F Urbanski
Journal:  Rejuvenation Res       Date:  2012-04       Impact factor: 4.663

2.  Age-associated gene expression changes in the arcuate nucleus of male rhesus macaques.

Authors:  Dominique H Eghlidi; Vasilios T Garyfallou; Steven G Kohama; Henryk F Urbanski
Journal:  J Mol Endocrinol       Date:  2017-06-14       Impact factor: 5.098

Review 3.  Role of circadian neuroendocrine rhythms in the control of behavior and physiology.

Authors:  Henryk F Urbanski
Journal:  Neuroendocrinology       Date:  2011-04-21       Impact factor: 4.914

4.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

5.  Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.

Authors:  Christin N Snyder; Richard V Clark; Ralph B Caricofe; Mark A Bush; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2010-04-08

Review 6.  Age-related changes in neuroendocrine rhythmic function in the rhesus macaque.

Authors:  Henryk F Urbanski; Krystina G Sorwell
Journal:  Age (Dordr)       Date:  2011-12-25

7.  Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.

Authors:  John K Amory; Mark A Bush; Hui Zhi; Ralph B Caricofe; Alvin M Matsumoto; Ronald S Swerdloff; Christina Wang; Richard V Clark
Journal:  J Urol       Date:  2010-12-18       Impact factor: 7.450

8.  Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride.

Authors:  M Y Roth; R E Dudley; L Hull; A Leung; P Christenson; C Wang; R Swerdloff; J K Amory
Journal:  Int J Androl       Date:  2010-10-24

9.  Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods.

Authors:  Christina Wang; Steve Shiraishi; Andrew Leung; Sima Baravarian; Laura Hull; Victor Goh; Paul W N Lee; Ronald S Swerdloff
Journal:  Steroids       Date:  2008-05-21       Impact factor: 2.668

Review 10.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.